Clinical Trials Logo

Metastatic Malignant Melanoma clinical trials

View clinical trials related to Metastatic Malignant Melanoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01705392 Terminated - Clinical trials for Metastatic Malignant Melanoma

Bevacizumab vs Dacarbazine in Metastatic Melanoma

Start date: January 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare efficacy of bevacizumab monotherapy with standard chemotherapy (DTIC) in patients with metastatic malignant melanoma. In addition, we want to evaluate the predictive value of a set biomarkers associated with vascular endothelial growth factor (VEGF) dependent angiogenesis. Also, we aim to identify mechanisms causing acquired resistance to treatment with bevacizumab and escape mechanisms caused by other angiogenic growth factors than VEGF. Finally, we want to analyze safety and influence on outcome variables by primary prevention of bevacizumab induced hypertension by low dose beta blockers in comparison with an ACE inhibitor.

NCT ID: NCT00961844 Terminated - Clinical trials for Metastatic Malignant Melanoma

Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma

Start date: August 2009
Phase: Phase 1/Phase 2
Study type: Interventional

In this trial the investigators want to combine chemotherapy with immunotherapy by giving the patients Temozolomide, before vaccination. The investigators have also included hTERT and survivin mRNA in the vaccine. Finally, the investigators want to introduce ex vivo T cell expansion after lymphodepletion for the patients who show an immune response.

NCT ID: NCT00304200 Terminated - Clinical trials for Metastatic Malignant Melanoma

Temodar and Sutent as Therapy for Melanoma

Start date: March 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to evaluate the safety and appropriate dose of the combination of Temodar and Sutent as first-line therapy for patients with metastatic malignant melanoma (Phase 1). Once the safety and appropriate dose is determined, additional patients will be studied at that dose to determine if there is clinical benefit as determined by the primary end-point of progression-free survival (PFS) at 6 months and additional secondary endpoints (Phase II).